Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (14362)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 14, 2018 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 195-210 [PMID: 29375205 DOI: 10.3748/wjg.v24.i2.195] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v24/i2/195.htm |
| Number | Citing Articles |
| 1 |
Xiao-Xiao Wang, Rui Jin, Xiao-He Li, Qiang Yang, Xiao Teng, Fang-Fang Liu, Nan Wu, Hui-Ying Rao, Feng Liu. Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1172058
|
| 2 |
Hideki Mori, Gianluca Svegliati Baroni, Marco Marzioni, Francesca Di Nicola, Pierangelo Santori, Luca Maroni, Ludovico Abenavoli, Emidio Scarpellini. Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota. Metabolites 2022; 12(7): 647 doi: 10.3390/metabo12070647
|
| 3 |
Ruicong Sun, Chunjin Xu, Baisui Feng, Xiang Gao, Zhanju Liu. Critical roles of bile acids in regulating intestinal mucosal immune responses. Therapeutic Advances in Gastroenterology 2021; 14 doi: 10.1177/17562848211018098
|
| 4 |
Shifat-E Ferdous, Jessica M. Ferrell. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches. International Journal of Molecular Sciences 2024; 25(16): 8731 doi: 10.3390/ijms25168731
|
| 5 |
Reeju Amatya, Donghee Lee, Kyoung Ah Min, Meong Cheol Shin. Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy. Pharmaceutics 2023; 15(7): 1963 doi: 10.3390/pharmaceutics15071963
|
| 6 |
Justine Gillard, Corinne Picalausa, Christoph Ullmer, Luciano Adorini, Bart Staels, Anne Tailleux, Isabelle A. Leclercq. Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. Nutrients 2022; 14(13): 2707 doi: 10.3390/nu14132707
|
| 7 |
Beatrice Anfuso, Claudio Tiribelli, Luciano Adorini, Natalia Rosso. Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-58562-x
|
| 8 |
Marlena M. Holter, Margot K. Chirikjian, Viraj N. Govani, Bethany P. Cummings. TGR5 Signaling in Hepatic Metabolic Health. Nutrients 2020; 12(9): 2598 doi: 10.3390/nu12092598
|
| 9 |
Jonathan D. Roth, Sanne S. Veidal, Louise K. D. Fensholdt, Kristoffer T. G. Rigbolt, Romeo Papazyan, Jens Christian Nielsen, Michael Feigh, Niels Vrang, Mark Young, Jacob Jelsing, Luciano Adorini, Henrik H. Hansen. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-45178-z
|
| 10 |
Josué Orozco-Aguilar, Felipe Simon, Claudio Cabello-Verrugio, Anwen Shao. Redox‐Dependent Effects in the Physiopathological Role of Bile Acids. Oxidative Medicine and Cellular Longevity 2021; 2021(1) doi: 10.1155/2021/4847941
|
| 11 |
Justine Gillard, Isabelle A. Leclercq. Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease. Clinical Science 2023; 137(1): 65 doi: 10.1042/CS20220697
|
| 12 |
Dieter Schmoll, Nicole Ziegler, Benoit Viollet, Marc Foretz, Patrick C. Even, Dalila Azzout‐Marniche, Andreas Nygaard Madsen, Martin Illemann, Karen Mandrup, Michael Feigh, Jörg Czech, Heiner Glombik, Jacob A. Olsen, Wolfgang Hennerici, Klaus Steinmeyer, Ralf Elvert, Tamara R. Castañeda, Aimo Kannt. Activation of Adenosine Monophosphate—Activated Protein Kinase Reduces the Onset of Diet‐Induced Hepatocellular Carcinoma in Mice. Hepatology Communications 2020; 4(7): 1056 doi: 10.1002/hep4.1508
|
| 13 |
Hong Wang, Qingxian He, Guangji Wang, Xiaowei Xu, Haiping Hao. FXR modulators for enterohepatic and metabolic diseases. Expert Opinion on Therapeutic Patents 2018; 28(11): 765 doi: 10.1080/13543776.2018.1527906
|
| 14 |
Veronika A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022; 10(2): 274 doi: 10.3390/biomedicines10020274
|
| 15 |
Verena Keitel, Jan Stindt, Dieter Häussinger. Bile Acids and Their Receptors. Handbook of Experimental Pharmacology 2019; 256: 19 doi: 10.1007/164_2019_230
|
| 16 |
Qixiang Zhao, Jiayu Wu, Yong Ding, Yanli Pang, Changtao Jiang. Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions. Life Metabolism 2023; 2(6) doi: 10.1093/lifemeta/load032
|
| 17 |
Raquel Benedé-Ubieto, Francisco Javier Cubero, Yulia A. Nevzorova. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes 2024; 16(1) doi: 10.1080/19490976.2024.2331460
|
| 18 |
Meng-jun Chen, Chen Liu, Yue Wan, Lei Yang, Shu Jiang, Da-wei Qian, Jin-ao Duan. Enterohepatic circulation of bile acids and their emerging roles on glucolipid metabolism. Steroids 2021; 165: 108757 doi: 10.1016/j.steroids.2020.108757
|
| 19 |
Michele Biagioli, Silvia Marchianò, Cristina Di Giorgio, Martina Bordoni, Ginevra Urbani, Rachele Bellini, Carmen Massa, Rana Sami Ullah Khan, Rosalinda Roselli, Maria Chiara Monti, Elva Morretta, Antonino Giordano, Valentina Vellecco, Mariarosaria Bucci, Asif Jilani Iqbal, Anella Saviano, Adel Ab Mansour, Patrizia Ricci, Eleonora Distrutti, Angela Zampella, Enrico Cieri, Giuseppe Cirino, Stefano Fiorucci. Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease. Biochemical Pharmacology 2023; 218: 115900 doi: 10.1016/j.bcp.2023.115900
|
| 20 |
Jin Chen, Minghua Zheng, Jun Liu, Yan Luo, Wenjun Yang, Jing Yang, Juan Liu, Jingxing Zhou, Chengfu Xu, Faling Zhao, Mingming Su, Shufei Zang, Junping Shi. Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis. Obesity 2019; 27(12): 2055 doi: 10.1002/oby.22627
|
| 21 |
Chao Li, Jie Yang, Yu Wang, Yingzi Qi, Wenqing Yang, Yunlun Li. Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.01247
|
| 22 |
L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, Lenka Maletínská. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. Frontiers in Endocrinology 2020; 11 doi: 10.3389/fendo.2020.597583
|
| 23 |
Shinobu Miyazaki-Anzai, Masashi Masuda, Shohei Kohno, Moshe Levi, Yuji Shiozaki, Audrey L. Keenan, Makoto Miyazaki. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. Journal of Lipid Research 2018; 59(9): 1709 doi: 10.1194/jlr.M087239
|
| 24 |
Bruno Cerra, Francesco Venturoni, Maria Souma, Giada Ceccarelli, Anna Maria Lozza, Daniela Passeri, Francesca De Franco, Ian R. Baxendale, Roberto Pellicciari, Antonio Macchiarulo, Antimo Gioiello. Development of 3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-sulfate sodium salt (INT-767): Process optimization, synthesis and characterization of metabolites. European Journal of Medicinal Chemistry 2022; 242: 114652 doi: 10.1016/j.ejmech.2022.114652
|
| 25 |
Sachiho Miyata, Yuji Kawashima, Miku Sakai, Masaya Matsubayashi, Keisuke Motoki, Yui Miyajima, Yousuke Watanabe, Noriko Chikamatsu, Tetsuya Taniguchi, Ryukou Tokuyama. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-88493-0
|
| 26 |
Wenhua Shao, Mayuko Ichimura-Shimizu, Hirohisa Ogawa, Shengjian Jin, Mitsuko Sutoh, Satoko Nakamura, Miki Onodera, Hirosuke Tawara, Shunji Toyohara, Ryoji Hokao, Yasusei Kudo, Takeshi Oya, Koichi Tsuneyama. Establishment of repeated liver biopsy technique in experimental mice. Heliyon 2023; 9(6): e16978 doi: 10.1016/j.heliyon.2023.e16978
|
| 27 |
Miha Jerala, Tinkara Remic, Nina Hauptman, Pia Homan, Neža Zajšek, Mathieu Petitjean, Li Chen, Nina Zidar. Thrombospondin 2, matrix Gla protein and digital analysis identified distinct fibroblast populations in fibrostenosing Crohn’s disease. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-64672-7
|
| 28 |
Henrik H. Hansen, Helene M. Ægidius, Denise Oró, Simon S. Evers, Sara Heebøll, Peter Lykke Eriksen, Karen Louise Thomsen, Anja Bengtsson, Sanne S. Veidal, Michel Feigh, Malte P. Suppli, Filip K. Knop, Henning Grønbæk, Diego Miranda, James L. Trevaskis, Niels Vrang, Jacob Jelsing, Kristoffer T. G. Rigbolt. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01356-2
|
| 29 |
Chang Han. Update on FXR Biology: Promising Therapeutic Target?. International Journal of Molecular Sciences 2018; 19(7): 2069 doi: 10.3390/ijms19072069
|
| 30 |
Ting-ying Jiao, Yuan-di Ma, Xiao-zhen Guo, Yun-fei Ye, Cen Xie. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacologica Sinica 2022; 43(5): 1103 doi: 10.1038/s41401-022-00880-z
|
| 31 |
James Hutchenreuther, John Nguyen, Katherine Quesnel, Krista M. Vincent, Louis Petitjean, Sophia Bourgeois, Mark Boyd, George Bou-Gharios, Lynne-Marie Postovit, Andrew Leask. Cancer-associated Fibroblast–specific Expression of the Matricellular Protein CCN1 Coordinates Neovascularization and Stroma Deposition in Melanoma Metastasis. Cancer Research Communications 2024; 4(2): 556 doi: 10.1158/2767-9764.CRC-23-0571
|
| 32 |
Henrik H. Hansen, Gitte Hansen, Thomas Secher, Michael Feigh, Sanne S. Veidal, Keld Fosgerau, Jacob Jelsing, Niels Vrang. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019; : 369 doi: 10.1007/978-3-030-11748-1_14
|
| 33 |
Claire C.J. Groenen, Thuc-Anh Nguyen, Coen C. Paulusma, Stan F.J. van de Graaf. Bile salt signaling and bile salt-based therapies in cardiometabolic disease. Clinical Science 2024; 138(1): 1 doi: 10.1042/CS20230934
|
| 34 |
Jingwei Cai, Bipin Rimal, Changtao Jiang, John Y.L. Chiang, Andrew D. Patterson. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacology & Therapeutics 2022; 237: 108238 doi: 10.1016/j.pharmthera.2022.108238
|
| 35 |
Radina Kostadinova, Simon Ströbel, Li Chen, Katia Fiaschetti‑Egli, Jana Gadient, Agnieszka Pawlowska, Louis Petitjean, Manuela Bieri, Eva Thoma, Mathieu Petitjean. Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-55438-2
|
| 36 |
Laura G. Di Pasqua, Marta Cagna, Giuseppina Palladini, Anna C. Croce, Massimiliano Cadamuro, Luca Fabris, Stefano Perlini, Luciano Adorini, Andrea Ferrigno, Mariapia Vairetti. FXR agonists INT‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH. Liver International 2024; 44(1): 214 doi: 10.1111/liv.15767
|
| 37 |
Richard Radun, Michael Trauner. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Seminars in Liver Disease 2021; 41(04): 461 doi: 10.1055/s-0041-1731707
|
| 38 |
Michelle L Boland, Denise Oró, Kirstine S Tølbøl, Sebastian T Thrane, Jens Christian Nielsen, Taylor S Cohen, David E Tabor, Fiona Fernandes, Andrey Tovchigrechko, Sanne S Veidal, Paul Warrener, Bret R Sellman, Jacob Jelsing, Michael Feigh, Niels Vrang, James L Trevaskis, Henrik H Hansen. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World Journal of Gastroenterology 2019; 25(33): 4904-4920 doi: 10.3748/wjg.v25.i33.4904
|
| 39 |
Maria Nicoline Baandrup Kristiansen, Sanne Skovgård Veidal, Christina Christoffersen, Michael Feigh, Niels Vrang, Jonathan David Roth, Mary Erickson, Luciano Adorini, Jacob Jelsing. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterology 2019; 19(1) doi: 10.1186/s12876-019-1149-z
|
| 40 |
Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo. Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond. Biomedicines 2024; 12(2): 397 doi: 10.3390/biomedicines12020397
|
| 41 |
Ming Gu, Yaru Feng, Yujun Chen, Shengjie Fan, Cheng Huang. Deoxyschizandrin ameliorates obesity and non‐alcoholic fatty liver disease: Involvement of dual Farnesyl X receptor/G protein‐coupled bile acid receptor 1 activation and leptin sensitization. Phytotherapy Research 2023; 37(7): 2771 doi: 10.1002/ptr.7770
|
| 42 |
Andreas Luxenburger, Lawrence D. Harris, Elizabeth M. Ure, Wanting Jiao, Anthony D. Woolhouse, Scott A. Cameron, Alex Weymouth-Wilson, Richard H. Furneaux, Janet L. Pitman, Simon F.R. Hinkley. The discovery of 12β-methyl-17-epi-18-nor-bile acids as potent and selective TGR5 agonists. European Journal of Medicinal Chemistry 2023; 250: 115143 doi: 10.1016/j.ejmech.2023.115143
|
| 43 |
Shuni Duan, Xiaojiaoyang Li, Guifang Fan, Runping Liu. Targeting bile acid signaling for the treatment of liver diseases: From bench to bed. Biomedicine & Pharmacotherapy 2022; 152: 113154 doi: 10.1016/j.biopha.2022.113154
|
| 44 |
Christina Lamers, Daniel Merk. Anti-fibrotic Drug Discovery. 2020; : 76 doi: 10.1039/9781788015783-00076
|
| 45 |
Alessia Perino, Hadrien Demagny, Laura Velazquez-Villegas, Kristina Schoonjans. Molecular physiology of bile acid signaling in health, disease, and aging. Physiological Reviews 2021; 101(2): 683 doi: 10.1152/physrev.00049.2019
|
| 46 |
Mengjiao Zhou, Danfeng Wang, Xiang Li, Ying Cao, Chengxue Yi, Dickson Kofi Wiredu Ocansey, Yuling Zhou, Fei Mao. Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1016836
|
| 47 |
Shengying Qian, Xiaolin Wang, Yingfen Chen, Qiuhong Zai, Yong He. Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets. Seminars in Liver Disease 2024; 44(03): 319 doi: 10.1055/a-2338-9261
|
| 48 |
Caihua Wang, Chunpeng Zhu, Liming Shao, Jun Ye, Yimin Shen, Yuezhong Ren. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators of Inflammation 2019; 2019: 1 doi: 10.1155/2019/7659509
|
| 49 |
Martine C. Morrison, Lars Verschuren, Kanita Salic, Joanne Verheij, Aswin Menke, Peter Y. Wielinga, Marta Iruarrizaga‐Lejarreta, Laurent Gole, Wei‐Miao Yu, Scott Turner, Martien P.M. Caspers, Ibon Martínez‐Arranz, Elsbet Pieterman, Reinout Stoop, Arianne van Koppen, Anita M. van den Hoek, José M. Mato, Roeland Hanemaaijer, Cristina Alonso, Robert Kleemann. Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice. Hepatology Communications 2018; 2(12): 1513 doi: 10.1002/hep4.1270
|
| 50 |
Jiezhong Chen, Michael Thomsen, Luis Vitetta. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. Journal of Cellular Biochemistry 2019; 120(3): 2713 doi: 10.1002/jcb.27635
|
| 51 |
Benoit Smeuninx, Ebru Boslem, Mark A. Febbraio. Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease. Cancers 2020; 12(7): 1714 doi: 10.3390/cancers12071714
|
| 52 |
Kirstine S. Tølbøl, Birgit Stierstorfer, Jörg F. Rippmann, Sanne S. Veidal, Kristoffer T. G. Rigbolt, Tanja Schönberger, Matthew P. Gillum, Henrik H. Hansen, Niels Vrang, Jacob Jelsing, Michael Feigh, Andre Broermann. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences 2019; 64(5): 1238 doi: 10.1007/s10620-018-5395-7
|
| 53 |
Luciano Adorini, Kristoffer Rigbolt, Michael Feigh, Jonathan Roth, Mary Erickson, Matias A. Avila. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. PLOS ONE 2024; 19(4): e0300809 doi: 10.1371/journal.pone.0300809
|
| 54 |
Peng Zhao, Sheng-Na Han, Suyavaran Arumugam, Muhammad Nadeem Yousaf, Yanqin Qin, Joy X. Jiang, Natalie Julia Torok, Yonglin Chen, Mohd Salah Mankash, Junbao Liu, Jiansheng Li, Yasuko Iwakiri, Xinshou Ouyang. Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation. American Journal of Physiology-Gastrointestinal and Liver Physiology 2019; 317(4): G387 doi: 10.1152/ajpgi.00054.2019
|
| 55 |
Simona De Marino, Carmen Festa, Valentina Sepe, Angela Zampella. Bile Acids and Their Receptors. Handbook of Experimental Pharmacology 2019; 256: 137 doi: 10.1007/164_2019_237
|
| 56 |
Meilin Wei, Wei Tu, Genhua Huang. Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions. Frontiers in Microbiology 2024; 15 doi: 10.3389/fmicb.2024.1341938
|
| 57 |
Margaux Nawrot, Simon Peschard, Sophie Lestavel, Bart Staels. Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism 2021; 123: 154844 doi: 10.1016/j.metabol.2021.154844
|
| 58 |
Valérie Duvivier, Stéphanie Creusot, Olivier Broux, Aurélie Helbert, Ludovic Lesage, Kevin Moreau, Nicolas Lesueur, Lindsay Gerard, Karine Lemaitre, Nicolas Provost, Edwige-Ludiwyne Hubert, Tania Baltauss, Angelique Brzustowski, Nathalie De Preville, Julia Geronimi, Lucie Adoux, Franck Letourneur, Adel Hammoutene, Dominique Valla, Valérie Paradis, Philippe Delerive. Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs. Journal of Clinical and Experimental Hepatology 2022; 12(2): 293 doi: 10.1016/j.jceh.2021.09.001
|
| 59 |
Rakesh Sahu, Rakhi Mishra, Chandana Majee. An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance. Expert Review of Gastroenterology & Hepatology 2020; 14(10): 985 doi: 10.1080/17474124.2020.1797485
|
| 60 |
Xiaoxin X. Wang, Cen Xie, Andrew E. Libby, Suman Ranjit, Jonathan Levi, Komuraiah Myakala, Kanchan Bhasin, Bryce A. Jones, David J. Orlicky, Shogo Takahashi, Alexander Dvornikov, David E. Kleiner, Stephen M. Hewitt, Luciano Adorini, Jeffrey B. Kopp, Kristopher W. Krausz, Avi Rosenberg, James L. McManaman, Charles E. Robertson, Diana Ir, Daniel N. Frank, Yuhuan Luo, Frank J. Gonzalez, Enrico Gratton, Moshe Levi. The role of FXR and TGR5 in reversing and preventing progression of Western diet–induced hepatic steatosis, inflammation, and fibrosis in mice. Journal of Biological Chemistry 2022; 298(11): 102530 doi: 10.1016/j.jbc.2022.102530
|